Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS EXPANDS COLLABORATION WITH CANADIAN NUCLEAR LABORATORIES TO ACCELERATE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE

Defence Therapeutics Inc. has strengthened its long-standing collaboration with Canadian Nuclear Laboratories as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program.

Defence has been collaborating with CNL on the development of an Accum-enhanced radio-immunoconjugate program. This program is approaching a key inflection point, with critical results being generated by both lab teams on this program that are intended to support candidate selection and enable preparation for first-in-human clinical studies.

Based on the exciting traction on the lead program, Defence and CNL are expanding their collaboration to initiate multiple other radioisotope programs with Defence's proprietary Accum, positioning the company to rapidly expand its radiopharmaceutical portfolio as new data and strategic priorities emerge.

Radiopharmaceutical therapies require precise intracellular and nuclear localization to maximize efficacy as radioactive payloads must reach the vicinity of the cell nucleus to induce lethal DNA damage. Defence's proprietary Accum platform enables active intracellular and nuclear transport, unlocking the full therapeutic potential of targeted radiotherapies while increasing potency and reducing toxicity.

"This collaboration with CNL has become a cornerstone of our radiopharmaceutical strategy," said Sebastien Plouffe, chief executive officer of Defence Therapeutics. "Radiopharmaceuticals now represent one of our top development priorities alongside our ADC program. By deepening our work with CNL and leveraging their world-class nuclear science expertise, we are building a strong, proprietary pipeline in this space and accelerating our path toward the clinic."

"We have worked in close collaboration with Defence on their flagship program, delivering the technical results they require, and we are proud to contribute meaningfully to the advancement of their radiopharmaceutical pipeline," said Dr. Monica Regalbuto, vice-president, science and technology, at CNL. "We look forward to contributing our nuclear science expertise to help advance these programs toward the clinic."

This collaboration further strengthens Defence's position in precision intracellular drug delivery and radiopharmaceutical development, supporting its strategy to transform advanced biologics into safer, more effective first line cancer therapies.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.